Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 1
Treatment-assignment count: 0
Stratification count: 0
pancreatic cancer · Monoclonal Antibody
ALK fusion is flagged as low public signal because public trials show inclusion required evidence in 2 contexts. FDA CDx context should be reviewed manually.
Strongest role: Inclusion Required
Inclusion-required count: 1
Treatment-assignment count: 0
Stratification count: 0
Threshold count: 0
Common snippets: None extracted
Threshold label: Low
CDx label: Fda Cdx Context Manual Review Required
CDx maturity score: 2/5
Confidence: Medium
Signal count: 0
Recent signals: 0
Density label: Low
https://clinicaltrials.gov/study/NCT00042939 | https://clinicaltrials.gov/study/NCT07396090